Preserve003 ONC392 vs docetaxel Prog. NSCLC after PD inhibitors (Non-Small Cell Lung Cancer) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find the most effective, safe dose of an experimental drug called ONC-392 (the study drug). We want to know how well it works compared to the standard chemotherapy drug, docetaxel, for treating NSCLC.

¿Cuál es la Condición que se está estudiando?

Metastatic Non-Small Cell Lung Cancer (NSCLC)

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with metastatic NSCLC
Have metastases to regional lymph nodes or distant organs
Had their disease progress after treatment
Do not have metastases to the brain
Do not have documented targetable mutations or genomic alterations in the following genes: EGFR, ROS1, MET, BRAF, RET, NTRK, ALK, or HER2

For more information, contact the study team at annemarie.peters@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) a 1 de 2 grupos. You will either:

Get the study drug while you take part in the study; OR
Get the standard treatment for your diagnosis, doetaxel

Both the study drug and standard treatment are given as intravenous (IV) infusions. No matter to which group you are assigned, you will get a drug infusion every 3 weeks. You will receive up to 17 infusions.